1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AZ Heads Talk Pipeline And Partnerships

 
• By Kevin Grogan

The drugs major believes it has assembled a pipeline that is looking well stocked for several years to come.

Seeds
AZ lining up some promising early-stage projects • Source: Shutterstock

Having presented a very strong set of second-quarter results with a number of new products close to blockbuster status already, AstraZeneca PLC has highlighted some pipeline programs that it hopes will become future growth drivers.

Speaking to journalists to discuss the Q2 financials on 25 July, Mene Pangalos, head of biopharmaceuticals R&D at AstraZeneca, said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

More from R&D